Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Can Biocon, Mylan...

    Can Biocon, Mylan drugs be used for early breast cancer, asks Delhi HC

    Written by supriya kashyap kashyap Published On 2017-02-18T15:02:10+05:30  |  Updated On 18 Feb 2017 3:02 PM IST

    New Delhi : Can pharma majors Biocon and Mylan's generic breast cancer drugs, similar to that of their competitor Roche, be prescribed for early breast cancer and metastatic gastric cancer?


    This is an issue on which the Delhi High Court will start hearing arguments next week.



    Presently Biocon and Mylan's medications are prescribed only for metastatic breast cancer, as a single judge bench of the high court had restrained them from selling them for the other two diseases.

    However, both companies have approvals from the Drugs Controller General of India (DCGI) to sell their respective medicines for the other two cancers also, a decision which has been challenged by Roche.

    A bench of justices Badar Durrez Ahmed and Sanjeev Sachdeva asked Swiss pharma major Roche whether, as an interim measure, the other two companies can be allowed to sell their drugs in respect of early breast cancer and metastatic gastric cancer.

    Roche, represented by senior advocates Rajiv Nayar and Sandeep Sethi, sought that no orders should be passed to allow Biocon and Mylan to sell their medicine for the other two cancers, without first hearing it.

    On Roche's challenge to the approvals granted by DCGI, the bench was of the view that the company cannot challenge the approvals in a civil suit in court.

    DCGI, meanwhile, told the court that the approvals were rightly given.

    Biocon, represented by senior advocate Pratibha M Singh, and Mylan, represented by senior advocates C S Vaidyanathan and Amit Sibal, said they were unable to sell their medicines for early breast cancer and metastatic gastric cancer due to the single judge's interim order of August 13, 2015 and, as a result, Roche had a monopoly on the medication for the two diseases.

    The court was hearing Biocon and Mylan's appeal against the August 13, 2015 order which was passed in Roche's suit claiming passing off of their breast cancer drugs by the two companies.

    Biocon and Mylan have taken the stand that Roche no longer holds a patent in India for Trastuzumab, the salt used for making the breast cancer medication.


    Amit SibalBadar Durrez AhmedBioconbreast cancerC S VaidyanathancancerDelhi high courtgastric cancerMylanPratibha M SinghRajiv NayarRocheSandeep SethiSanjeev SachdevaTrastuzumab
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok